Compass Pathways stock sank Thursday, after the London-based psychedelic-drug developer held to its plans to report clinical-trial next year and noted "a number of differences" between its approach to psychedelics and that of Oregon, where voters last week legalized psilocybin therapy. This video file cannot be played. (Error Code: 102630)
Are compass pathways's earnings expected to increase or decrease this year?
Nov 09, 2021 · Why Compass Pathways Shares Are Slumping More Than 22% Tuesday By Jim Halley - Nov 9, 2021 at 3:48PM Key Points The company announced positive news out of its phase IIB trial for its lead therapy....
What is compass pathways'stock symbol?
Apr 03, 2022 · Earnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.85) to ($3.37) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of COMPASS Pathways is -7.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Price to Earnings Ratio vs. Sector
How many shares did compass pathways issue in its IPO?
Nov 09, 2021 · By RTTNews Staff Writer | Published: 11/9/2021 10:35 AM ET. Shares of COMPASS Pathways plc ( CMPS) tanked over 25% on Tuesday morning despite the company reporting positive results from a mid-stage trial of its COMP360 psilocybin therapy for treatment-resistant depression. CMPS is currently trading at $31.77, down $11.29 or 26.23%, on the …
What are analysts'target prices for Compass pathways'stock?
Apr 19, 2022 · Analysts Expect COMPASS Pathways plc (NASDAQ:CMPS) Will Post Earnings of -$0.68 Per Share americanbankingnews.com - April 9 at 12:18 AM: COMPASS Pathways (NASDAQ:CMPS) Trading Down 6.1% americanbankingnews.com - April 8 at 12:46 PM: COMPASS Pathways (NASDAQ:CMPS) Shares Gap Up to $13.37 americanbankingnews.com - April 5 at …
Is Compass stock a good buy?
There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Compass stock. View analyst ratings for Compass or view top-rated stocks.
Is COMPASS Pathways a buy?
COMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Is CMPS a good buy?
Out of 6 analysts, 4 (66.67%) are recommending CMPS as a Strong Buy, 2 (33.33%) are recommending CMPS as a Buy, 0 (0%) are recommending CMPS as a Hold, 0 (0%) are recommending CMPS as a Sell, and 0 (0%) are recommending CMPS as a Strong Sell. What is CMPS's earnings growth forecast for 2022-2024?
Is COMPASS Pathways publicly traded?
Psilocybin Magic Mushrooms are Now a Publicly Traded Investment Vehicle: COMPASS Pathways (NASDAQ:CMPS)Mar 28, 2022
Who owns Compass pharmaceuticals?
Several years ago our co-founders, George Goldsmith and Ekaterina Malievskaia, experienced the painful effects of depression within their own family. They discovered first-hand how hard it can be to find adequate mental health care for a loved one, and met many other patients and families who felt similarly helpless.
Does Atai own compass?
Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each and Atai paid around $12 million in total.Nov 29, 2021
Who is CMPS stock?
As of April 20 12:10PM EDT. Market open....Performance Outlook.Previous Close12.68Ask12.70 x 1200Day's Range12.29 - 12.7752 Week Range10.50 - 49.51Volume60,8163 more rows
Is Jazz Pharmaceuticals a buy?
Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Is Atai a buy?
Out of 10 analysts, 6 (60%) are recommending ATAI as a Strong Buy, 3 (30%) are recommending ATAI as a Buy, 1 (10%) are recommending ATAI as a Hold, 0 (0%) are recommending ATAI as a Sell, and 0 (0%) are recommending ATAI as a Strong Sell. What is ATAI's earnings growth forecast for 2022-2024?
How do I buy a compass pathways stock?
How to buy shares in COMPASS PathwaysCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Is Compass pathways a pharmaceutical company?
Compass Pathways Plc operates as a pharmaceutical company. The Company develops active substance psilocybin for the treatment of patients with treatment resistant depression.
When did compass pathways go public?
September 18th, 2020On September 18th, 2020 Compass Pathways was listed (NASDAQ:CMPS, ISIN:US20451W1018), making it the first psychedelic company to be listed on a U.S. exchange.Oct 1, 2020
Is COMPASS Pathways a buy right now?
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 8 buy rati...
When is COMPASS Pathways' next earnings date?
COMPASS Pathways is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for COMPA...
How were COMPASS Pathways' earnings last quarter?
COMPASS Pathways plc (NASDAQ:CMPS) announced its earnings results on Thursday, February, 24th. The company reported ($0.61) earnings per share for...
What price target have analysts set for CMPS?
8 Wall Street analysts have issued 12-month target prices for COMPASS Pathways' shares. Their forecasts range from $50.00 to $120.00. On average, t...
Who are COMPASS Pathways' key executives?
COMPASS Pathways' management team includes the following people: Mr. George Jay Goldsmith , Co-Founder, Chair of the Board & CEO (Age 67, Pay $7...
Who are some of COMPASS Pathways' key competitors?
Some companies that are related to COMPASS Pathways include Zentalis Pharmaceuticals (ZNTL) , Sage Therapeutics (SAGE) , Ironwood Pharmaceutical...
What other stocks do shareholders of COMPASS Pathways own?
Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA) , Va...
When did COMPASS Pathways IPO?
(CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cow...
What is COMPASS Pathways' stock symbol?
COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression.
COMPASS Pathways (NASDAQ:CMPS) Frequently Asked Questions
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COMPASS Pathways stock. View analyst ratings for COMPASS Pathways or view top-rated stocks.
It depends on how optimistic you are about its lead program
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.
Valuation isn't an exact science
Since its initial public offering (IPO) in September of 2020, Compass has been busying developing its psychedelic therapies. Because it doesn't have any products approved for sale yet, it presently has no revenue or earnings to speak of.
Psilocybin might be useful in more common varieties of depression
In the long run, it's possible that COMP360 will be proven useful for wider indications within the field of depression and its related disorders. The company is already conducting research with the help of collaborators to evaluate the therapy's efficacy for major depressive disorder (MDD), suicidal ideation, and bipolar disorder.
Where is compass pathways based?
COMPASS Pathways ( CMPS - Get Rating) is a mental healthcare business based in London, UK. However, CMPS principally operates in New York. CMPS is down nearly 30% year to date, presenting a potentially lucrative entry point for investors who have been waiting to establish a position in the stock.
When did CMPS jump?
CMPS was trading in the mid-$30s in April, then jumped up to $39 on April 27. Profit-taking caused the stock to drop to $35 the next day. However, CMPS bounced right back to life, returning to $38.96 one day later. Unfortunately, CMPS has stagnated in the weeks since, trading between $36 and $32.
How many people benefit from Comp360?
It is estimated that more than 100 million individuals across the globe can benefit from COMP360. There is also the potential for CMPS psychedelics to help individuals with maladies aside from depression. It is interesting to note CMPS will not strictly provide patients with only COMP360.
What is the lowest target price for CMPS?
The lowest target price for CMPS is $50. CMPS’s upside potential is 80% higher than the rest of the stocks traded in the United States. Furthermore, the average analyst price target for CMPS is greater than 93% of all small-cap stocks.
Does CMPS provide Comp360?
It is interesting to note CMPS will not strictly provide patients with only COMP360. Rather, the drug will be provided in unison with the assistance of mental health professionals. The bottom line is no one knows for sure exactly how the general public will react to micro dosing psychedelics to overcome depression.